New Systemic Treatment Options for Radioiodine-Refractory Differentiated and Medullary Thyroid Cancers

The aim of this evaluation form is to gain your feedback, in order to maintain high educational standards and provide a reference for continuous improvement. Please indicate which rating reflects your answer.

Questions marked with are required.

1. Has this module enabled you to describe epidemiology, pathogenesis, differential diagnosis, natural course and outcome of patients with thyroid cancer? (1-not at all; 5-absolutely)

2. Has this module enabled you to evaluate recent clinical trials data focused on the efficacy and safety of new systemic treatment options for radioiodine-refractory differentiated and medullary thyroid cancers? (1-not at all; 5-absolutely)

3. Has this module enabled you to employ best clinical practices regarding therapy selection to improve outcomes in patients with radioiodine-refractory differentiated and medullary thyroid cancers? (1-not at all; 5-absolutely)

4. Please, provide your overall rating of the quality of the education offered by this E-Learning module. (1-poor; 5-excellent)

5. How would you rate the interactivity level offered in the E-Learning material? (1-poor; 5-excellent)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-absolutely)

7. Do you feel that the information presented was well balanced and supported by adequate evidence? (1-not at all; 5-absolutely)

8. If you would like to add your personal comments or make suggestion to improve future ESMO E-Learning material, please write in the box below: